High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues

被引：70

作者：

Alvarez-Cedrón, L ^{[1
]}

Sayalero, ML ^{[1
]}

Lanao, JM ^{[1
]}

机构：

[1] Univ Salamanca, Dept Pharm & Pharmaceut Technol, Salamanca 37007, Spain

来源：

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 1999年 / 721卷 / 02期

关键词：

doxorubicin;

D O I：

10.1016/S0378-4347(98)00475-7

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

A specific and selective high-performance liquid chromatography (HPLC) technique that requires few manipulations, and is readily adaptable to analysis for a large series of samples, has been developed for the determination of the concentration of the anticancer drug doxorubicin (DXR) in rat serum and tissues. The biological samples were efficiently deproteinised and resolved from a reversed-phase nucleosil C-18 column with fluorescence detection. The validation study of the proposed method was successfully carried out in an assay range of between 5 and 5000 ng/ml and was subsequently implemented in a pharmacokinetic study of DXR in Wistar rats that were treated by intravenous administration of the drug. (C) 1999 Elsevier Science B.V. All rights reserved.

引用

页码：271 / 278

页数：8

共 12 条

[1] A SENSITIVE AND SIMPLE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF DOXORUBICIN AND ITS METABOLITES IN PLASMA [J].

ANDERSEN, A ;

WARREN, DJ ;

SLORDAL, L .

THERAPEUTIC DRUG MONITORING, 1993, 15 (05) :455-461

[2] HPLC DETERMINATION OF DOXORUBICIN, DOXORUBICINOL AND 4 AGLYCONE METABOLITES IN PLASMA OF AIDS PATIENTS [J].

BEIJNEN, JH ;

MEENHORST, PL ;

VANGIJN, R ;

FROMME, M ;

ROSING, H ;

UNDERBERG, WJM .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1991, 9 (10-12) :995-1002

[3] ANALYSIS OF ADRIAMYCIN AND ADRIAMYCINOL IN MICRO VOLUMES OF RAT PLASMA [J].

BOTS, AMB ;

VANOORT, WJ ;

NOORDHOEK, J ;

VANDIJK, A ;

KLEIN, SW ;

VANHOESEL, QGCM .

JOURNAL OF CHROMATOGRAPHY, 1983, 272 (02) :421-427

[4] A SENSITIVE AND REPRODUCIBLE HPLC ASSAY FOR DOXORUBICIN AND PIRARUBICIN [J].

JACQUET, JM ;

GALTIER, M ;

BRESSOLLE, F ;

JOURDAN, J .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1992, 10 (05) :343-348

[5] HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY DETERMINATION OF DOXORUBICIN AND DAUNORUBICIN IN PLASMA USING UV DETECTION AND COLUMN SWITCHING [J].

MIKAN, A ;

LANAO, JM ;

LOPEZ, FG ;

HURLE, ADG .

BIOMEDICAL CHROMATOGRAPHY, 1990, 4 (04) :154-156

[6] DOXORUBICIN CARDIOTOXICITY - ANALYSIS OF PREVAILING HYPOTHESES [J].

OLSON, RD ;

MUSHLIN, PS .

FASEB JOURNAL, 1990, 4 (13) :3076-3086

[7]

PETERS JH, 1981, CANCER CHEMOTH PHARM, V7, P65

[8] COMPARISON OF THE PHARMACOKINETICS OF MULTIPLE AND SINGLE DOSE ADMINISTRATIONS OF ADRIAMYCIN [J].

SIEMANN, DW ;

SUTHERLAND, RM .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1979, 5 (08) :1271-1274

[9] EFFECTS OF VERAPAMIL ON THE ACUTE TOXICITY OF DOXORUBICIN INVIVO [J].

SRIDHAR, R ;

DWIVEDI, C ;

ANDERSON, J ;

BAKER, PB ;

SHARMA, HM ;

DESAI, P ;

ENGINEER, FN .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (21) :1653-1660

[10] CARDIAC TOXICITY 4 TO 20 YEARS AFTER COMPLETING ANTHRACYCLINE THERAPY [J].

STEINHERZ, LJ ;

STEINHERZ, PG ;

TAN, CTC ;

HELLER, G ;

MURPHY, ML .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (12) :1672-1677

← 1 2 →